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Abstract  
Introduction: the paucity of data on hepatitis' epidemiology in Menoua Division, west region, Cameroon, prompted us to assess the prevalence of 
viral and non-viral hepatitis in this area. Methods: a retrospective exhaustive study based on records of patients from January 2008 to June 2014 
was conducted in 9 health centres in Menoua Division. Targeted subjects were patients who did not receive hepatitis vaccines for the past year and 
have been screened for hepatitis B virus (HBV), hepatitis C virus (HCV) and/or a blood transaminase. Associations between variables were quantified 
with odd ratios (OR) and 95% confidence interval (CI). Cochran-Armitage test of linear trend was used for testing proportions of ordinal variables. 
Fisher's exact test was used for testing the association between 2 qualitative variables when expected counts were less than 5. Results: the overall 
prevalence were 9.6% and 6.7% for HBV and HCV respectively. HBV mostly infected people aged 21-30 (12.4%) while the prevalence of HCV 
increased with age up to 35.4% (p=0.03). A 0.6% co-infection was observed. Thirty percent of positive HBV or HCV had high transaminase while 
13% of patients with elevated transaminase showed negative viral serology. Conclusion: these results show that hospital-based prevalence of HCV 
and HBV in Menoua Division is under the Cameroon's national range but point out the fact that non-viral hepatitis might be a serious case of concern 
in this area. There is therefore, a need to identify the risk-factors of non-viral hepatitis. 
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Hepatitis is a medical condition defined as inflammation of the liver 
and characterized by the presence of inflammatory cells in the liver 
parenchyma. There are several forms of hepatitis including viral, 
autoimmune [1], fatty liver [2], alcoholic [3], drug-induced- [4] and 
toxin-induced-hepatitis. It is assumed that most cases of hepatitis are 
due to viral infections [5] worldwide. As such, five classes of viral 
hepatitis (A, B, C, D and E) are described based on their transmission 
routes, incubation period, and evolutionary pattern of each virus [6]. 
According to the World Health Organization [7] approximately 325 
million people were living with chronic hepatitis infections (HBV or 
HCV) worldwide in 2015. It is estimated that 257 million people are 
living with hepatitis B virus infection while 71 million people have 
chronic hepatitis C infection. Africa has the highest prevalence of HCV, 
rated to 5.3% [8] and Cameroon is the second most afflicted with a 
prevalence of (4.9-13.8%) after Egypt (4.4-15.0%) [9]. Last 
epidemiology studies in Cameroon showed a prevalence of HBV of 
13% [10]. Level of education, marital status, multiples sexual 
partners, scarification or tattooing, blood transfusion and surgery 
history have been proven to be the main risk factors associated with 
HBV and HCV transmission in Cameroon [11]. Xenobiotic contributes 
15% to the yearly death rate due to hepatitis [12] with 2.5 million 
death recorded from alcoholic hepatotoxicity, representing 4% of 
worldwide mortality [13]. Cameroon's western region lacks critically 
data on hepatitis prevalence. In addition, there is no data regarding 
non-viral hepatitis in Cameroon, although the risk factors are 
prominent. Thus, this study was undertaken to assess viral (HBV, 
HCV) and non-viral hepatitis prevalence in Menoua Division, west 





Study area: the study was conducted in Menoua Division (Figure 1), 
one of the 6 Divisions of the western region of Cameroon. Its 
population is roughly 1 million inhabitants. 
  
Study design: a retrospective descriptive study was carried out to 
determine the evolution of the prevalence of viral hepatitis (HBsAg, 
anti-HCV) and non-viral hepatitis from 2008 to 2014 in Menoua 
Division. The hepatitis testing became available in many Menoua 
Subdivisions' health care centres from 2008. The nine most important 
health care centres of Menoua Division used in this study were: 
Dschang District hospital, Saint Vincent de Paul hospital, Ad Lucem 
hospital, Santchou Subdivision hospital, Fokoue Subdivision hospital, 
Fongo-Tongo Subdivision hospital, Nkong-ni CMA, Penka Michel 
District hospital, and Balesing CMA. Attendance registers and records 
from each health care centre were used. Parameters of interest were 
sex, age, town, serology and transaminases. 
  
Study population: the study population was made up of patients 
attending consultation from January 2008 to June 2014 in one of the 
nine health centres in Menoua Division selected for the study. 
Targeted subjects were those who have been screened for HBV, HCV 
and/or have been prescribed a blood transaminase assay. Patients 
who had received vaccine or who had missing information were 
excluded from the study. 
  
Serological tests: third generation Enzyme Linked Immuno-Sorbent 
Assay (ELISA) was used to determine the presence of hepatitis B 
surface antigen (HBsAg) or HCV antibodies. Patients were considered 
infected with HBV or HCV when they were positive to HBsAg or HCV 
antibodies, respectively. Blood transaminases were assayed using 
commercial kits, to assess liver damage. Blood transaminase values 
greater than 80 UI/L were considered high. 
  
Administrative authorisation: to conduct this study in the 
different health centres, administrative authorisations were obtained 
from the Health District of Menoua Division and the directors of the 
different health centres. 
  
Data and statistical analysis: qualitative variables were presented 
as percentages (%). Since age of patients deviated significantly from 
normal distribution, it was presented as median with Inter quartile 
range (IQR). The comparison of proportions was performed using 
Chi-square Test. Data were analysed using IBM-SPSS 21 (IBM SPSS 
Statistics for Windows, version 21 (IBM Corp., Armonk, N.Y., USA)). 
Associations were quantified using Odd ratios (OR) and 95% 
confidence interval (CI). Cochran- Armitage test of linear trend was 
used for testing proportions for ordinal variables. Fisher's Exact Test 
was used for testing association between 2 qualitative variables when 
expected counts were less than 5. P-values less than 5% were 








Among the patients screened for hepatitis or transaminases, 5337 
fulfilled the inclusive conditions and did not fall under exclusive ones. 
The selected patients were made up of 2796 (52.4%) males and 2541 
(47.6%) females with age ranging from 3 months to 101 years old 
with a median of 29 (IQR = 23-41 years). The number of patients 
screened increased significantly between 2008 and 2014 (P < 0.05) 
(Figure 2). 
  
Sex-dependent prevalence of viral hepatitis B and C: in the 
tested population made up of 2239 females and 2435 males, the 
prevalence of HBV was 9.6%. The odd of males to be HBV infected 
was 1.2 times that of women (OR = 1.17 (0.97-1.41; P = 0.09)) with 
a prevalence of 10.3 and 8.9% respectively. The overall prevalence 
of HCV was 6.7% with no significant difference (p = 0.78) between 
male (6.6%) and female (6.9%) (Table 1). 
  
Prevalence of viral hepatitis B and C according to age: with a 
prevalence of 12.4%, patients between 21-30 years were the most 
afflicted with HBV, followed by those aged of 31-40 (9.1%). The odds 
of individuals of age group 21-30 infected with HBV was 2.46 times 
higher than those of 0-10 (OR = 2.46 (1.19-5.09); P = 0.01). The 
prevalence of hepatitis C significantly increased with age (p=0.00) 
ranging between 2.5% to 4.7% for patients of 0-50 years. However, 
it significantly increases from 14.2 to 35.4% (p = 0.00) for the range 
51-80. Meanwhile, the most infected groups were 61-70 years 
(23.8%) and 71-80 years (35.4%) (Table 2). 
  
Year variations of the prevalence of viral hepatitis B and 
C: the highest prevalence of hepatitis B virus was 13% in 2011, 
followed by 12.5 and 11.3% obtained in 2012 and 2014, respectively. 
The prevalence of HBV increased linearly between 2008 and 2014 
(P = 0.03). The highest prevalence of HCV (9.4%) was obtained in 
2009 (Table 3). 
  
Prevalence of viral hepatitis B and C according to Sub-
division: out of the 6 Sub-divisions, Santchou and Dschang were the 
most affected with an overall prevalence of 10.5 and 9.9% 
respectively for HBV, while the highest prevalence of HCV was in 
Santchou (13.3%) (Table 4). 
  
Overall results of viral hepatitis B and C in the studied 
population: among the patients screened for both HBV and HCV, 
there were 0.6% co-infection. Among the 5337 patients included in 
the study, 86.0% neither had HBV nor HCV, while 13.4% either had 
(not both) HBV or HCV. 
  
Association between serological test and transaminase 
rate: out of the 5337 patients who underwent the viral serology tests, 
only 132 were screened for the level of transaminases. Thirty percent 
of the 132 patients had high transaminase (> 80 UI) level linked to 
either HBV or HCV positive serology. Among the HBV and HCV co-
infected patients, 20% had elevated level of transaminases. The last 
group (13%) showed a negative serology with a high level of 





This study aimed to assess the prevalence of viral and non-viral 
hepatitis in Menoua Division. It was found that the number of patients 
screened significantly increased with time between 2008 and 2014. 
This shows the increasing awareness of hepatitis in the general 
population. Furthermore, governmental policy has improved the 
availability of diagnostic tools which could also explain the increasing 
number of patients screened. Out of 5337 patients screened, 9.6% 
and 6.7% were infected respectively with HBV and HCV. The HBV 
prevalence of 9.6% obtained here is similar to the 9.2% recorded by 
Njouom [14] in the western region, but lower than the general 
prevalence in Cameroon (13%). Nevertheless, Menoua Division is still 
a region of concern. The high prevalence of HBV in the general 
population of Cameroon may be justified by the fact that screening, 
vaccination and treatment are by individual approaches [15]. 
Furthermore, the cost of the vaccination and screening test is still 
high for an average Cameroonian. Concerning HCV, several countries 
like Bolivia, Burundi, Cameroon, Egypt, Guinea, Mongolia, Rwanda 
and Tanzania have a prevalence above 10% [16], Cameroon being 
the second most affected after Egypt [9]. Results from the present 
study demonstrated that the prevalence of HCV in the Menoua 
Division is 6.7%. Although this prevalence is less than the general' 
observed in Cameroon (11.6%), it is higher than the 4.8% obtained 
by Noubiap et al. [17] in blood donors population in Edea, Cameroon. 
The HCV prevalence results corroborates with the 7.7% reported by 
Mbanya [18] among pregnant women in Yaoundé, Cameroon. It is 
worth noting that in Cameroon, HCV prevalence varies from simple to 
more than double from one region to another. Regional prevalence is 
therefore of a paramount importance in order to design management 
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strategies against the disease. Hepatitis B is more prevalent (13.8%) 
than hepatitis C (11.6%) in the general population of Cameroon [14] 
notwithstanding the prominent campaign of hepatitis B vaccine. 
Those findings are in line with results obtained in the present study 
and further indicate that there is still more to do in order to control 
the transmission of the disease. Particular attention needs to be paid 
on medical interventions, sexual activities and disease transmission 
from mother to child [19]. It was also noteworthy that until the end 
of 2014, it was still not possible to do HBV and HCV serological testing 
in Fokoué and Fongo-tongo Sub-divisions. This demonstrates the 
insufficiency of health care policy orientated to hepatitis in Cameroon, 
despite the efforts made by the government. 
  
Santchou Sub-division was the most affected by hepatitis B and 
hepatitis C, followed by Dschang Sub-division. The high prevalence 
observed in Santchou might likely be tributary to limited knowledge 
of this disease by its rural population mainly made up of farmers. In 
addition, Santchou is a cosmopolitan area compared to other Sub-
divisions. According to Blachier et al. [20], patients infected with 
hepatitis live in the high majority in peripheral areas of Africa and Asia 
where sensitization, screening and access to treatment is not easily 
available. The high prevalence observed in Dschang could also be 
explained by the high number of students arriving each year. Our 
results showed that men were mostly infected by HBV while women 
were the most infected by HCV. These results contrast with those got 
by Arifa [5] in three Pakistan Districts. Nevertheless, they are similar 
to those obtained by Ankouane [21] who checked the prevalence of 
hepatitis B in a population of bank employees in Cameroon according 
to age, the range 21-30 years was the most screened and showed 
the highest prevalence of HBV. This could be explained by the fact 
that young people in Cameroon usually get married at that age; 
moreover, some clinical examinations including hepatitis checking 
especially are part of their prenuptial preparations. These results 
agree with those previously obtained [14, 15, 18, 22]. The prevalence 
of HCV highly increased with age and the most affected people were 
those of 71-80 years (35.4%). Similar results were obtained by 
Pepin et al. [11] in Ebolowa where the prevalence was 56% in age 
group ≥ 60 years old. Thirty percent of patients who have underwent 
both the transaminase and viral serology test had high transaminase 
(> 80 UI) level associated to either HBV or HCV while 13% showed a 
negative serology with a high level of transaminase. This result 
indicates that viruses are not the sole cause of liver damage or liver 
disease. Non-viral factors may surely be highly involved. Megarbane 
[12] reported that 15% of hepatitis is caused by xenobiotics. Indeed, 
alcoholism is a source of liver injury, and lead to 2.5 million deaths 
each year [13]. Furthermore, William [23] reported that drug-induced 
hepatic injury is the most frequent reason and accounts for more than 
50 percent of the cases of acute liver failure in the United States. The 
use of some chemical reagents like carbon tetrachloride also produce 
liver damage [24, 25]. There are many other viruses bringing about 
hepatitis including cytomegalovirus, epstein-barr virus, yellow fever 
virus, mump virus and rubella virus [26] which may also account for 
this liver injury. Nevertheless, since Agriculture is the main activity in 
Menoua Division, huge quantities of pesticides is used without proper 
care; this could be another cause of liver damage. Whatever the case, 
it clearly appears that non-viral hepatitis is a serious case of concern 





The prevalence of viral hepatitis in Menoua Division is high though 
lower than the national rate. The HBV is more prominent than HCV 
but there is no difference as far as sex is concerned. Santchou Sub-
division was the most affected and people of 20-29 years are the most 
affected. The prevalence of non-viral hepatitis is also high in this 
region. 
  
Limits and recommendations: hepatitis management policy 
should consider both viral and non-viral types, especially in the 
Menoua division; update epidemiological data of infectious and non-
infectious hepatitis at regional and national levels to assist decision-
making; identify the risk-factors of non-viral hepatitis; sensitise the 
local population about the transmission of hepatitis and most 
importantly, on the precaution to avoid non-viral hepatitis.  
 
What is known about this topic 
 Cameroon is one of the countries with higher hepatitis 
prevalence; 
 The general prevalence of HBV in Cameroon is about 13%; 
 Africa has the highest prevalence of HCV, estimated to 
5.3%. 
What this study adds 
 This article presents for the first time, the prevalence of 
hepatitis in the Menoua Division (West Cameroon), and rise 
the case of non-viral hepatitis in the studied region; 
 The paper helps to understand that the causes of hepatitis 
in Menoua Division are not only viral. Indeed, the 
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Table 1: prevalence of hepatitis B and C with respect to sex 





Total OR 95%CI P 
  
Hepatitis B 
Female 2239 (91.1) 219 (8.9) 2458 1   
Male 2435 (89.7) 279 (10.3) 2714 1.17 0.97-1.41 0.09 
  Total 4674 (90.4) 498(9.6) 5172    
  
Hepatitis C 
Female 1590 (93.1) 117 (6.9) 1707 1   
Male 1917 (93.4) 136 (6.6) 2053 0.75 0.75-1.25 0.78 
  Total 3507(93.3) 253(6.7) 3760    
OR: odds Ratio value, CI: Confidence interval, P: P- value 
 
 
Table 2: prevalence of hepatitis B and C with respect to age (years)  
Characteristics Negative (%) 
Positive 
(%) 
Total OR 95%CI P 
Hepatitis B (P-value forCochran- 
Armitage test of linear trend=0.03) 
            
0-10 139 (94.6) 8 (5.4) 147 1   
11-20 624 (91.6) 57 (8.4) 681 1.59 0.74-3.40 0.23 
21-30 1616 (87.6) 229 (12.4) 1845 2.46 1.19-5.09 0.01 
31-40 868 (90.9) 87 (9.1) 955 1.74 0.82-3.68 0.14 
41-50 531 (91.9) 47(8.1) 578 1.53 0.71-3.33 0.27 
51-60 337 (92.3) 28 (7.7) 365 1.45 0.64-3.24 0.37 
61-70 174 (93.5) 12 (6.5) 186 1.19 0.47-3.02 0.70 
71 and more 98 (93.3) 7 (6.7) 105 1.24 0.43-3.53 0.68 
Total 4387(90.2) 475(9.8) 4862    
Hepatitis C (P-value forCochran- 
Armitage test of linear trend=0.00) 
      
0-10 79 (97.5) 2 (2.5) 81 1   
11-20 400 (95.5) 19 (4.5) 419 1.87 0.42-8.21 0.40 
21-30 1241(96.1) 50 (3.09) 1291 1.60 0.38-6.66 0.53 
31-40 714 (95.3) 35 (4.7) 749 1.93 0.46-8.20 0.38 
41-50 445 (95.3) 22 (4.7) 467 1.95 0.45-8.47 0.38 
51-60 253 (85.8) 42 (14.2) 295 6.56 1.55-27.70 0.11 
61-70 109 (76.2) 34 (23.8) 143 12.32 2.87-52.80 0.01 
71-80 53 (64.6) 29 (35.4) 82 21.62 4.94-94.43 0.00 
Total 3294(93.4) 233(6.6) 3527       
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Positive (%) Total OR 95%CI P 
Hepatitis B (P-value 
forCochran- Armitage test of 
linear trend=0.03) 
            
 2008 589  (93.6) 40 (6.4) 629 1   
2009 509 (92.0) 44 (8.0) 553 1.27 0.82-1.99 0.27 
2010 630 (91.2) 61(8.8) 691 1.42 0.94-2.16 0.09 
2011 669 (87.0) 100 (13.0) 769 2.20 1.50-3.22 0.00 
2012 741 (87.5) 106 (12.5) 847 2.10 1.44-3.08 0.00 
2013 977 (93.0) 73 (7) 1050 1.10 0.73-1.64 0.63 
2014 652 (88.7) 83 (11.3) 735 1.88 1.26-2.78 0.01 
Total 4767(90.4) 507(9.6) 5274    
Hepatitis  C (P-value 
forCochran- Armitage test of 
linear trend=0.052) 
      
2008 508 (92.5) 41 (7.5) 549 1   
2009 435 (90.6) 45 (9.4) 480 1.28 0.82-1.99 0.01 
2010 486 (91.7) 44 (8.3) 530 1.12 0.72-1.75 0.27 
2011 484 (96.8) 16 (3.2) 500 0.41 0.22-0.74 0.62 
2012 587 (94.7) 33 (5.3) 620 0.70 0.44-1.11 0.01 
2013 629 (92.8) 49 (7.2) 678 0.96 0.63-1.49 0.13 
2014 427(94.1) 27 (5.9) 454 0.79 0.47-1.30 0.88 
Total 3556(93.3) 255(6.7) 3811    
OR: odds Ratio value, CI: Confidence interval, P: P- value 
 
 
Table 4: prevalence of hepatitis B and hepatitis C with respect to sub-division 
Characteristics Negative (%) Positive (%) Total OR 95%CI P 
Hepatitis B (P-value 
for  Fisher's Exact 
Test=0.11) 
      
Dschang 4179 (90.1) 457 (9.9) 4636 1   
Nkong-Ni 191  (95.0) 10  (5.0) 201 0.48 0.25-0.91 0.02 
Penka Michel 363 (91.0) 36  (9.0) 399 0.90 0.63-1.30 0.60 
Santchou 34 (89.5) 4 (10.5) 38 1.08 0.39-3.05 0.90 
Total 4767 (90.4) 507 (9.6) 5274    
Hepatitis C (P-value 
for  Fisher's Exact 
Test=0.03) 
      
Dschang 3386 (93.1) 249 (6.9) 3635 1   
Penka -Michel 157  (97.5) 4 (2.5) 161 0.35 1.12-1.95 0.38 
Santchou 13   (86.7) 2 (13.3) 15 2.09 1.47-9.32 0.33 
Total 3556 (93.3) 255 (6.7) 3811    
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Table 5: association between serological test and rate of transaminase 
 












High level ALAT (P-value 
for  Fisher's Exact Test=0.17) 
    
No 64 (83.1) 20 (66.7) 4 (80.0) 88 (78.6) 
Yes 13 (16.9) 10 (33.3) 1 (20.0) 24 (21.4) 
Total  77 (100.0) 30(100.0) 5 (100.0) 
112 
(100.0) 
High level ASAT (P-value 
for  Fisher's Exact Test=0.02) 
    
No 63(81.8) 19 (63.3) 2 (40.0) 84 (75.0) 
Yes 14(18.2) 11 (36.7) 3 (60.0) 28 (25.0) 
Total 77(100.0) 30(100.0) 5(100.0) 
112 
(100.0) 
Either (not both) ALAT high or 
ASAT high (P-value for Fisher's 
Exact Test=0.11) 
    
No 60 (89.5) 18 (85.7) 2 (50.0) 80 (86.9) 
Yes 7 (10.5) 3 (4.3) 2 (50.0) 12 (13.1) 
Total 67(100) 21(100.0) 4(100.0) 92 (100.0) 
High level of both ALAT  and 
ASAT (P-value for  Fisher's Exact 
Test=0.05) 
    
No 60 (85.7) 18 (66.7) 2 (66.7) 80 (80.0) 
Yes 10 (14.3) 9 (33.3) 1(33.3) 20 (20.0) 
Total  70 (100.0) 27 (100.0) 3 (100.0) 
100 
(100.0) 
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Figure 1: geographical localisation of Menoua Division and the nine health centres 
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Figure 2: number of patients screened according to years 
 
